RecruitingPhase 1NCT05068674

Human Embryonic Stem Cell-Derived Cardiomyocyte Therapy for Chronic Ischemic Left Ventricular Dysfunction

A Phase I, Randomized Pilot Study of Human Embryonic Stem Cell-Derived Cardiomyocytes (hESC-CMs) in PaTients With ChrOnic Ischemic Left VentRicular Dysfunction Secondary to Myocardial Infarction (HECTOR)

Sponsor

Joseph C. Wu

Enrollment

18 participants

Start Date

Mar 22, 2022

Study Type

INTERVENTIONAL

Conditions

Chronic Ischemic Left Ventricular Dysfunction

Summary

This clinical study will utilize a new cell therapy approach (Human embryonic stem cells derived cardiomyocytes or hESC-CMs) to improve survival and cardiac function in patients with chronic left ventricular dysfunction secondary to MI (Myocardial Infarction).

Eligibility

Min Age: 21 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Human Embryonic Stem Cell-Derived Cardiomyocyte 150 cells, a drug called Human Embryonic Stem Cell-Derived Cardiomyocyte 300M cells, and others for people with chronic ischemic left ventricular dysfunction. The study is currently recruiting participants at 1 location. People eligible for this study include aged 21 Years to 80 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGHuman Embryonic Stem Cell-Derived Cardiomyocyte 50M cells

50 million (M) cells delivered in a dose of 5M cells per injection over 10 injections.

DRUGHuman Embryonic Stem Cell-Derived Cardiomyocyte 150 cells

150M cells delivered in a dose of 15M cells per injection over 10 injections

DRUGHuman Embryonic Stem Cell-Derived Cardiomyocyte 300M cells

300M cells delivered in a dose of 30M per injection over 10 injections

Locations(1)

Stanford Hospital and Clinics

Palo Alto, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05068674